Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 4, 2016, Pages 309-317

  Heerspink, Hiddo J L ^a   Persson, Frederik ^b   Brenner, Barry M ^c   Chaturvedi, Nish ^d   Brunel, Patrick ^e   McMurray, John J ^f   Desai, Akshay S ^c   Solomon, Scott D ^c   Pfeffer, Marc A ^c   Parving, Hans Henrik ^g   de Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b STENO DIABETES CENTER   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EARLY TERMINATION OF CLINICAL TRIAL; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; FOLLOW UP; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDY; NETHERLANDS; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; URINE;

AGED; ALBUMINURIA; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CREATININE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FUMARATES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NETHERLANDS; PREVALENCE; PROGNOSIS; SURVIVAL RATE;

EID: 84954286946     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00469-6     Document Type: Article

References (30)

1. Brewster UC, Setaro JF, Perazella MA The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003, 326:15-24.
2. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 2014, 10:243.
3. Kunz R, Friedrich C, Wolbers M, Mann JF Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30-48.
4. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446. for the AVOID Study Investigators.
5. Skeggs LT, Kahn JR, Lentz K, Shumway NP The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957, 106:439-453.
6. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32:1873-1879.
7. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
8. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
9. Ruggenenti P, Perna A, Remuzzi G Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003, 63:2254-2261.
10. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663-1671.
11. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
12. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
13. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821.
14. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D Microalbuminuria: target for renoprotective therapy PRO. Kidney Int 2014, 86:40-49.
15. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
16. Fried LF, Lewis J Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view. Clin J Am Soc Nephrol 2015, 10:1089-1093.
17. Lambers Heerspink HJ, Gansevoort RT Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol 2015, 10:1079-1088.
18. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
19. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
20. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
21. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
22. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007, 30:1577-1578.
23. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364:907-917.
24. Lambers Heerspink HJ, de Zeeuw D Dual RAAS blockade has dual effects on outcome. Nat Rev Endocrinol 2013, 9:261-263.
25. Apperloo AJ, de Zeeuw D, de Jong PE A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997, 51:793-797.
26. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011, 80:282-287.
27. de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883-892.
28. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369:1892-1903.
29. Grams ME, Sang Y, Ballew SH, et al. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis 2015, 66:591-601.
30. Okusa MD, Davenport A Reading between the (guide)lines-the KDIGO practice guideline on acute kidney injury in the individual patient. Kidney Int 2014, 85:39-48.